Ann Arbor-based NanoBio Corp. said Tuesday that it will present new data on its clinical and preclinical trials of new treatments for toenail fungus, cold sores and cystic fibrosis, as well as a new nasal-spray influenza vaccine, at a medical conference next week.
NanoBio will make a total of nine presentations at the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America in Washington, D.C., Oct. 25-28.
NanoBio will also exhibit at corporate booth #408.
Its presentation schedule will be as follows:
Sunday, Oct. 26: 11:15 a.m. to 12:15 p.m., "A Novel Nanoemulsion Adjuvant Enhancing the Immune Response to ß-propiolactone Inactivated Influenza Virus Using a Nasal Route in a Ferret Model," Poster #G-1194
Monday, Oct. 27: "Novel Nanoemulsion NB-001 Permeates Skin by the Follicular Route," Poster #A-1898; "NB-002, a Novel Nanoemulsion with Anti-Dermatophyte Activity," Poster #M-2134; and "Mechanism of Skin Penetration and Distribution of a Novel Nanoemulsion," Poster #M-2135, all 11:15 a.m. to 12:15 p.m.; and "Safety, Tolerability and Pharmacokinetics of NB-001 in a Phase 2 Dose-Ranging Trial in Subjects with Recurrent Herpes Labialis," Presentation #V-3539; and "A Novel Nanoemulsion Active Against Acyclovir (ACV)- and Foscarnet (FOS)-Resistant Herpes Simplex Virus (HSV) 1 and 2," Poster #V-3538, both 12:15 to 1:15 p.m.
Tuesday, Oct. 28: "Oral Presentation: Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis," 9 to 9:15 a.m.; and "Novel Nanoemulsion Antimicrobials Tested Against Nine Gram-Positive Species," Poster #F1-3944; and "Antimicrobial Activity of Nanoemulsions Tested Against Seven Gram-Negative Species," Poster #F1-3945, both 11:15 a.m. to 12:15 p.m.
NanoBio is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat technology platform. The company’s lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B.
More at www.nanobio.com
E-Mail Story
Print Story
